NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.